221 related articles for article (PubMed ID: 34175539)
1. Camptothecin's journey from discovery to WHO Essential Medicine: Fifty years of promise.
Khaiwa N; Maarouf NR; Darwish MH; Alhamad DWM; Sebastian A; Hamad M; Omar HA; Orive G; Al-Tel TH
Eur J Med Chem; 2021 Nov; 223():113639. PubMed ID: 34175539
[TBL] [Abstract][Full Text] [Related]
2. The long story of camptothecin: From traditional medicine to drugs.
Martino E; Della Volpe S; Terribile E; Benetti E; Sakaj M; Centamore A; Sala A; Collina S
Bioorg Med Chem Lett; 2017 Feb; 27(4):701-707. PubMed ID: 28073672
[TBL] [Abstract][Full Text] [Related]
3. An overview on the development of new potentially active camptothecin analogs against cancer.
Chazin Ede L; Reis Rda R; Junior WT; Moor LF; Vasconcelos TR
Mini Rev Med Chem; 2014; 14(12):953-62. PubMed ID: 25355593
[TBL] [Abstract][Full Text] [Related]
4. From Lead to Drug Utilizing a Mannich Reaction: The Topotecan Story.
Bracher F; Tremmel T
Arch Pharm (Weinheim); 2017 Jul; 350(7):. PubMed ID: 27805723
[TBL] [Abstract][Full Text] [Related]
5. A Review on Camptothecin Analogs with Promising Cytotoxic Profile.
Amin SA; Adhikari N; Jha T; Gayen S
Anticancer Agents Med Chem; 2018; 18(13):1796-1814. PubMed ID: 29589546
[TBL] [Abstract][Full Text] [Related]
6. Novel E-ring camptothecin keto analogues (S38809 and S39625) are stable, potent, and selective topoisomerase I inhibitors without being substrates of drug efflux transporters.
Takagi K; Dexheimer TS; Redon C; Sordet O; Agama K; Lavielle G; Pierré A; Bates SE; Pommier Y
Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3229-38. PubMed ID: 18089716
[TBL] [Abstract][Full Text] [Related]
7. Camptothecin-7-yl-methanthiole: semisynthesis and biological evaluation.
Christodoulou MS; Zunino F; Zuco V; Borrelli S; Comi D; Fontana G; Martinelli M; Lorens JB; Evensen L; Sironi M; Pieraccini S; Dalla Via L; Gia OM; Passarella D
ChemMedChem; 2012 Dec; 7(12):2134-43. PubMed ID: 23086693
[TBL] [Abstract][Full Text] [Related]
8. Recent advances in topoisomerase I-targeting agents, camptothecin analogues.
Kim DK; Lee N
Mini Rev Med Chem; 2002 Dec; 2(6):611-9. PubMed ID: 12370044
[TBL] [Abstract][Full Text] [Related]
9. Structural insight of DNA topoisomerases I from camptothecin-producing plants revealed by molecular dynamics simulations.
Sirikantaramas S; Meeprasert A; Rungrotmongkol T; Fuji H; Hoshino T; Sudo H; Yamazaki M; Saito K
Phytochemistry; 2015 May; 113():50-6. PubMed ID: 25733498
[TBL] [Abstract][Full Text] [Related]
10. Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan.
Mathijssen RH; Loos WJ; Verweij J; Sparreboom A
Curr Cancer Drug Targets; 2002 Jun; 2(2):103-23. PubMed ID: 12188913
[TBL] [Abstract][Full Text] [Related]
11. [Camptothecin and derivatives: a new class of antitumor agents].
Torck M; Pinkas M
J Pharm Belg; 1996; 51(4):200-7. PubMed ID: 8965250
[TBL] [Abstract][Full Text] [Related]
12. Camptothecin and its analogues: a review on their chemotherapeutic potential.
Sriram D; Yogeeswari P; Thirumurugan R; Bal TR
Nat Prod Res; 2005 Jun; 19(4):393-412. PubMed ID: 15938148
[TBL] [Abstract][Full Text] [Related]
13. [The other camptothecins: recent advances with camptothecin analogues other than irinotecan and topotecan].
Lavergne O; Bigg DC
Bull Cancer; 1998 Dec; Spec No():51-8. PubMed ID: 9932086
[TBL] [Abstract][Full Text] [Related]
14. Clinical pharmacology of camptothecins.
Iyer L; Ratain MJ
Cancer Chemother Pharmacol; 1998; 42 Suppl():S31-43. PubMed ID: 9750027
[TBL] [Abstract][Full Text] [Related]
15. Topoisomerase I inhibitors. An overview of the camptothecin analogs.
Burris HA; Fields SM
Hematol Oncol Clin North Am; 1994 Apr; 8(2):333-55. PubMed ID: 8040144
[TBL] [Abstract][Full Text] [Related]
16. Antitumor effect of DX-8951, a novel camptothecin analog, on human pancreatic tumor cells and their CPT-11-resistant variants cultured in vitro and xenografted into nude mice.
Takiguchi S; Kumazawa E; Shimazoe T; Tohgo A; Kono A
Jpn J Cancer Res; 1997 Aug; 88(8):760-9. PubMed ID: 9330608
[TBL] [Abstract][Full Text] [Related]
17. DNA topoisomerase I changes the mode of interaction between camptothecin drugs and DNA as probed by UV-resonance Raman spectroscopy.
Feofanov AV; Baranov AV; Fleury F; Riou JF; Nabiev IR; Manfait M
FEBS Lett; 1996 Nov; 396(2-3):289-92. PubMed ID: 8915005
[TBL] [Abstract][Full Text] [Related]
18. Preclinical evaluation of CPT-11 and its active metabolite SN-38.
Lavelle F; Bissery MC; André S; Roquet F; Riou JF
Semin Oncol; 1996 Feb; 23(1 Suppl 3):11-20. PubMed ID: 8633248
[TBL] [Abstract][Full Text] [Related]
19. Review camptothecin: current perspectives.
Li QY; Zu YG; Shi RZ; Yao LP
Curr Med Chem; 2006; 13(17):2021-39. PubMed ID: 16842195
[TBL] [Abstract][Full Text] [Related]
20. Camptothecin and taxol: discovery to clinic.
Wall ME
Med Res Rev; 1998 Sep; 18(5):299-314. PubMed ID: 9735871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
